



**Nixi Laboratories Pvt. Ltd.**  
VPO: Mouza Ogli, Sadhora Road, Kala Amb Distt. Sirmour (H.P)

**CERTIFICATE OF ANALYSIS FINISHED PRODUCTS**

Product Name	TEICOCAN-400	AR. No.	NL/DI/FG/24/840
Generic Name	Teicoplanin Injection IP		
Mother Batch No.	D24AY009	Reference	IP/IHS
Child Batch No.	D24AY009H	Batch Size	550 Vials
Mfg. Date	09/2024	Exp. Date	08/2026
Specification No. (STS No)	QC/DPI/FG/STS/011-02	Standard Test Procedure No.	QC/DPI/FG/STP/011
Sample Quantity	45 Vials	Sampled Date	24/09/2024
Released Date	08/10/2024		

Sr.No.	TEST	SPECIFICATION	OBSERVATION
1.	Description	White or off white to yellowish powder filled in 10 ml clear glass vial, plugged with rubber stopper and sealed with flip off aluminum seal.	off white to Yellowish powder filled in 10 ml clear glass vial, plugged with rubber stopper and sealed with flip off aluminum seal.
2.	Identification: (A) By UV-visible Spectrophotometer  (B) By High Performance Liquid Chromatography (HPLC)	It shows an absorption maximum at about 278 nm.  In composition and related substances obtained the principal peaks (Teicoplanins A <sub>3-1</sub> , A <sub>2-1</sub> , A <sub>2-2</sub> , A <sub>2-3</sub> , A <sub>2-4</sub> , and A <sub>2-5</sub> ) in the chromatogram obtained with the test solution corresponds to the principal peak in the chromatogram obtained with the reference solution.	Complies  Complies
3.	Clarity of solution	a) The solid dissolves completely, leaving no visible residue as undissolved matter. b) The constituted injection is not significantly less clear than an equal volume of the diluent or of water for injections contained in a similar container and examined in the same	Complies  Complies
4.	Average filled weight	415 mg ± 5%	410.5 mg
5.	Uniformity of weight	Average filled weight ± 5.0%	-1.03%, + 0.89%

	ANALYSED BY	CHECKED BY	APPROVED BY
Name	Tarun Kumar	Akhilak	Aditya Singh
Signature			
Date	08/10/24	08/10/24	08/10/24





**Nixi Laboratories Pvt. Ltd.**  
VPO: Mouza Ogli, Sadhora Road, Kala Amb Distt. Sirmour (H.P)

**CERTIFICATE OF ANALYSIS FINISHED PRODUCTS**

<b>Product Name</b>	TEICOCAN-400	<b>AR. No.</b>	NL/DI/FG/24/840
<b>Generic Name</b>	Teicoplanin Injection IP		
<b>Mother Batch No.</b>	D24AY009	<b>Reference</b>	IP/IHS
<b>Child Batch No.</b>	D24AY009H	<b>Batch Size</b>	550 Vials
<b>Mfg. Date</b>	09/2024	<b>Exp. Date</b>	08/2026
<b>Specification No. (STS No)</b>	QC/DPI/FG/STS/011-02	<b>Standard Test Procedure No.</b>	QC/DPI/FG/STP/011
<b>Sample Quantity</b>	45 Vials	<b>Sampled Date</b>	24/09/2024
<b>Released Date</b>	08/10/2024		

6.	<b>pH</b>	6.0 to 8.0	6.84
7.	<b>Particulate matter</b>		
	<b>For Visible Particles:</b>	Should be free from visible particles	Complies
	For sub visible particles		
	(i) Equal to or greater than 10µm	NMT 6000 particles/container	1764.0 particles/container
	(ii) Equal to or greater than 25µm	NMT 600 particles/container	58.7 particles/container
8.	<b>Sterility</b>	Should comply the test of sterility	Complies
9.	<b>Bacterial Endotoxins</b>	NMT 0.30 EU/mg of Teicoplanin	Complies
10.	<b>Water content</b>	NMT 5.0 %	4.10 %
11.	<b>Composition &amp; Related substances</b>		
	(i) Teicoplanin A <sub>2</sub> group	NLT 75 %	84.83%
	(ii) Teicoplanin A <sub>3</sub> group	NMT 20 %	12.18%
	(iii) Sum of all other Secondary impurity	NMT 5.0 %	2.99%
12.	<b>Assay:</b>		
	Each Vial contains: Teicoplanin IP 400 mg	360.00 mg to 480.00 mg (90.00 % To 120.00 %)	406.56 mg (101.64%)

**RESULT:** The above sample **COMPLIES/DOES NOT COMPLY** as per Specification No- QC/DPI/FG/STS/011-02.

**Conclusion:** In the opinion of the under signed the sample referred above is of **STANDARD QUALITY / IS NOT STANDARD QUALITY** as defined in the Drugs & Cosmetics Act, 1940 and the rules made here under further

	<b>ANALYSED BY</b>	<b>CHECKED BY</b>	<b>APPROVED BY</b>
<b>Name</b>	Tarun Kumar	Akhilak	Aditya Singh
<b>Signature</b>			
<b>Date</b>	08/10/24	08/10/24	08/10/24

